The association between the gut microbiome and antituberculosis drug-induced liver injury
BackgroundThis study aimed to explore the distinct characteristics of the gut microbiota in tuberculosis (TB) patients who experienced liver injury following anti-TB treatment compared with those who did not.MethodWe employed a nested case-control study design, recruiting newly diagnosed pulmonary T...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512815/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250378494345216 |
|---|---|
| author | Shengfei Pei Li Yang Huixia Gao Yuzhen Liu Jianhua Lu Er hei Dai Chunyan Meng Fumin Feng Yuling Wang |
| author_facet | Shengfei Pei Li Yang Huixia Gao Yuzhen Liu Jianhua Lu Er hei Dai Chunyan Meng Fumin Feng Yuling Wang |
| author_sort | Shengfei Pei |
| collection | DOAJ |
| description | BackgroundThis study aimed to explore the distinct characteristics of the gut microbiota in tuberculosis (TB) patients who experienced liver injury following anti-TB treatment compared with those who did not.MethodWe employed a nested case-control study design, recruiting newly diagnosed pulmonary TB patients at Tangshan Infectious Disease Hospital. Participants were categorized into the Antituberculosis Drug-Induced Liver Injury (ADLI) group and the Non-ADLI group based on the occurrence of liver injury after treatment. Both groups received identical anti-TB regimens. Stool samples were collected from patients who developed liver injury within 2–3 weeks of starting treatment, alongside matched controls during the same timeframe. The samples underwent 16S rDNA sequencing, and clinical data and blood samples were also collected for further analysis. At the same time, we constructed mouse models to explore the effects of different anti-tuberculosis drugs on gut microbiota.ResultsFollowing anti-TB treatment, we observed a decrease in microbial diversity and significant structural changes in the gut microbiota of TB patients (P < 0.05). At T1, the Non_ADLI_T1 group presented relatively high levels of Phascolarctobacterium, Anaerofustis and Mailhella. In contrast, the ADLI_ T1 group presented elevated levels of Bacteroides, Veillonella, Clavibacter, Corynebacterium, Anaerococcus, Gardnerella, Peptostreptococcus and Lautropia. At T2, the ADLI_T2 group presented increased levels of Enterococcus, Faecalibacterium, unclassified_f__Burkholderiaceae, Cardiobacterium, Ruminococcus_gnavus_group and Tyzzerella_4 than did the Non_ADLI_T2 group. Additionally, the ADLI_T2 group presented decreased levels of Prevotella_9, Akkermansia, Erysipelotrichaceae_UCG-003, Rubrobacter and norank_f__Desulfovibrionaceae than did the Non_ADLI_T2 group. In animal experiments, similar changes to those in the human population were observed in the mouse model compared to the control group. Any single anti-tuberculosis drug or two-drug combination or three-drug combination can cause dysbiosis of the mouse gut microbiota. The signature genera between groups are different and related to the type of anti-tuberculosis drug.ConclusionAnti-tuberculosis treatment induces dysbiosis in the gut microbiota of TB patients. Notably, there are significant differences in microbiota characteristics between TB patients with and without liver injury at both onset and during treatment. There are some differences in the characteristics of bacterial flora in liver injury caused by different drugs. |
| format | Article |
| id | doaj-art-c44d6919a19e421a8225d280df447d8a |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-c44d6919a19e421a8225d280df447d8a2025-08-20T01:58:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15128151512815The association between the gut microbiome and antituberculosis drug-induced liver injuryShengfei Pei0Li Yang1Huixia Gao2Yuzhen Liu3Jianhua Lu4Er hei Dai5Chunyan Meng6Fumin Feng7Yuling Wang8Hebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science of Technology, Tangshan, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaHebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science of Technology, Tangshan, ChinaHebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science of Technology, Tangshan, ChinaHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital ofShijiazhuang, Shijiazhuang, ChinaBackgroundThis study aimed to explore the distinct characteristics of the gut microbiota in tuberculosis (TB) patients who experienced liver injury following anti-TB treatment compared with those who did not.MethodWe employed a nested case-control study design, recruiting newly diagnosed pulmonary TB patients at Tangshan Infectious Disease Hospital. Participants were categorized into the Antituberculosis Drug-Induced Liver Injury (ADLI) group and the Non-ADLI group based on the occurrence of liver injury after treatment. Both groups received identical anti-TB regimens. Stool samples were collected from patients who developed liver injury within 2–3 weeks of starting treatment, alongside matched controls during the same timeframe. The samples underwent 16S rDNA sequencing, and clinical data and blood samples were also collected for further analysis. At the same time, we constructed mouse models to explore the effects of different anti-tuberculosis drugs on gut microbiota.ResultsFollowing anti-TB treatment, we observed a decrease in microbial diversity and significant structural changes in the gut microbiota of TB patients (P < 0.05). At T1, the Non_ADLI_T1 group presented relatively high levels of Phascolarctobacterium, Anaerofustis and Mailhella. In contrast, the ADLI_ T1 group presented elevated levels of Bacteroides, Veillonella, Clavibacter, Corynebacterium, Anaerococcus, Gardnerella, Peptostreptococcus and Lautropia. At T2, the ADLI_T2 group presented increased levels of Enterococcus, Faecalibacterium, unclassified_f__Burkholderiaceae, Cardiobacterium, Ruminococcus_gnavus_group and Tyzzerella_4 than did the Non_ADLI_T2 group. Additionally, the ADLI_T2 group presented decreased levels of Prevotella_9, Akkermansia, Erysipelotrichaceae_UCG-003, Rubrobacter and norank_f__Desulfovibrionaceae than did the Non_ADLI_T2 group. In animal experiments, similar changes to those in the human population were observed in the mouse model compared to the control group. Any single anti-tuberculosis drug or two-drug combination or three-drug combination can cause dysbiosis of the mouse gut microbiota. The signature genera between groups are different and related to the type of anti-tuberculosis drug.ConclusionAnti-tuberculosis treatment induces dysbiosis in the gut microbiota of TB patients. Notably, there are significant differences in microbiota characteristics between TB patients with and without liver injury at both onset and during treatment. There are some differences in the characteristics of bacterial flora in liver injury caused by different drugs.https://www.frontiersin.org/articles/10.3389/fphar.2025.1512815/fullpulmonary tuberculosisanti-TB therapymicrobiome dysbiosisprobioticsdrug-induced liver injury |
| spellingShingle | Shengfei Pei Li Yang Huixia Gao Yuzhen Liu Jianhua Lu Er hei Dai Chunyan Meng Fumin Feng Yuling Wang The association between the gut microbiome and antituberculosis drug-induced liver injury Frontiers in Pharmacology pulmonary tuberculosis anti-TB therapy microbiome dysbiosis probiotics drug-induced liver injury |
| title | The association between the gut microbiome and antituberculosis drug-induced liver injury |
| title_full | The association between the gut microbiome and antituberculosis drug-induced liver injury |
| title_fullStr | The association between the gut microbiome and antituberculosis drug-induced liver injury |
| title_full_unstemmed | The association between the gut microbiome and antituberculosis drug-induced liver injury |
| title_short | The association between the gut microbiome and antituberculosis drug-induced liver injury |
| title_sort | association between the gut microbiome and antituberculosis drug induced liver injury |
| topic | pulmonary tuberculosis anti-TB therapy microbiome dysbiosis probiotics drug-induced liver injury |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1512815/full |
| work_keys_str_mv | AT shengfeipei theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT liyang theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT huixiagao theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT yuzhenliu theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT jianhualu theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT erheidai theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT chunyanmeng theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT fuminfeng theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT yulingwang theassociationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT shengfeipei associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT liyang associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT huixiagao associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT yuzhenliu associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT jianhualu associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT erheidai associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT chunyanmeng associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT fuminfeng associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury AT yulingwang associationbetweenthegutmicrobiomeandantituberculosisdruginducedliverinjury |